Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa versus placebo in low- or intermediate-1-risk myelodysplastic syndromes at risk for transfusion
2008-002723-85Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of epoetin alfa in myelodysplastic syndrome (MDS) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of subjects remaining transfusion free from Day 29 through Week 48. Started Jan 2009; status: terminated.
02
Drugs
epoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2008-002723-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002723-85.